Clinical Trial Update: UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF [Phase 2]

View source ↗

Summary

An update on the adaptive Phase IIb platform trial UMIT-2 evaluating therapeutics for Crimean-Congo Hemorrhagic Fever; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crimean-congo Hemorrhagic Fever

Snippet

Sponsor: Liverpool School of Tropical Medicine | Conditions: Crimean-Congo Hemorrhagic Fever | Phase 2 | Status: NOT_YET_RECRUITING